XML 49 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Marketable Debt and Equity Securities - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Schedule of Available-for-sale Securities        
Net gain (loss) recorded on equity securities $ (12,027) $ 288 $ (9,702) $ (2,610)
Unrealized gain (loss) on equity securities (10,015) 288 (10,529) (2,610)
Impairment on equity securities $ 220 0 (20,430) 0
Zenas        
Schedule of Available-for-sale Securities        
Impairment on equity securities     $ (20,400)  
Astria | Common Stock | License        
Schedule of Available-for-sale Securities        
Sale of common stock (in shares) 443,909   443,909  
Number of shares owned (in shares) 253,958   253,958  
Astria/Catabasis | Technology License Agreement        
Schedule of Available-for-sale Securities        
Unrealized gain (loss) on equity securities $ (1,300) (3,500) $ 400 (3,900)
INmune | License        
Schedule of Available-for-sale Securities        
Unrealized gain (loss) on equity securities $ (5,500) 4,900 $ (4,600) 5,200
INmune | Common Stock | License        
Schedule of Available-for-sale Securities        
Number of shares owned (in shares) 1,885,533   1,885,533  
Viridian | Technology License Agreement        
Schedule of Available-for-sale Securities        
Unrealized gain (loss) on equity securities $ (3,200) $ (1,200) $ (6,300) $ (3,900)
Viridian | Common Stock | Technology License Agreement        
Schedule of Available-for-sale Securities        
Number of shares owned (in shares) 717,144   717,144